AKKARAJU SRINIVAS sold $1.0M of ALMS (indirect holdings)

AKKARAJU SRINIVAS sold 96,131 indirectly-held shares of ALUMIS INC. (ALMS) at $10.55 ($1.01M total) across 2 trades on 2026-09-08.

Original reporting
SEC EDGAR · AKKARAJU SRINIVAS
Published Sep 10, 2026, 1:39 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALMS
Bearish
medium confidence
Mentioned
$ALMS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALMSBearishLow
01

Why it matters

A $1M sale by a director may prompt short-term traders to consider selling pressure.

02

Market read

Primary relevance is to ALMS shareholders; broader market impact is negligible.

03

What to watch

Insider retains over 2 million shares, indicating continued confidence.

Relevance 6/10Novelty 4/10Timing: post-market 2026-09-08

Background

Form 4 filings disclose insider transactions; director sales are monitored for sentiment.

Company-level read

Ticker impact

$ALMSBearishMedium confidence
Context

Director Akkaraju Srinivas sold 96,131 shares for $1.014M on 2026-09-08.

Expected impact

Potential modest dip in ALMS price over the next few days.

Evidence & confidence

Director sales are often viewed as bearish, but the amount is modest relative to total holdings.

Market effects

Minimal impact on the construction materials sector.

No significant regional effect.

Limited to investors tracking insider activity.

Counterpoint

The sale could be a routine portfolio rebalancing, not a negative signal.

Key entities

  • Alumis Inc.

    US-listed construction materials firm (ticker ALMS).

  • Akkaraju Srinivas

    Director of Alumis who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALMSMed

Alumis Reports Q3 2026 Results, $94.9 Million Net Loss

Alumis reported Q3 2026 revenue of $1.9M and a net loss of $94.9M. Cash reserves totaled $431.3M, expected to last into Q4 2027. The company plans to submit an NDA for envudeucitinib in plaque psoriasis by Q4 2026, with positive Phase 3 data for scalp psoriasis. A Phase 2b trial in lupus did not meet primary endpoints, but a subgroup showed responses. Alumis will start a Phase 2 trial for A-005 in Parkinson's in 2027.

$ALMSHigh

Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates

ALUMIS INC. (ALMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. ​ Exhibit 99.1 ​ ​ Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates ​ – New Phase 3 data demonstrated rapid and durable improvements in plaque psoriasis burden, adding to envudeucitinib’s differentiated clinical profile, including the hig

$ALMSHighAI 8/10

Alumis (ALMS) Faces Pressure After Clinical Results

Voya MI Dynamic Small Cap Fund reported that its overweight position in Alumis (ALMS) hurt performance due to disappointing clinical trial results. ALMS closed at $6.62 with a $883.74M market cap, up 25.38% over 52 weeks. The fund's Q3 2026 letter cited sector performance variations, with energy, tech, and healthcare outperforming.